Are brigatinib and brigatinib the same drug?

Brigatinib and Brigatinib (Brigatinib) are actually the same drug, but they are just different expressions of the Chinese name. This phenomenon is not uncommon in the Chinese translation of international drug names and results from different translation habits, differences in transliteration, and different titles in official and unofficial documents. Whether it is "Brigatinib" or "Brigatinib", its common English name is "Brigatinib". Its pharmacological mechanism, indications, molecular structure and therapeutic effects are completely the same, so it is considered to be the same drug in clinical medicine.

Brigatinib is a second-generation ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor, mainly used to treat patients with ALK fusion gene-positive non-small cell lung cancer (NSCLC). This drug can effectively deal with the resistance problems caused by first-generation ALK inhibitors such as crizotinib, and especially shows stronger inhibitory effects on certain resistance mutation sites (such as G1202R mutation). In addition, it has good central nervous system penetration and can control brain metastases, making it an important treatment option for patients with ALK-positive lung cancer.

Regarding the difference in Chinese names,"Brigatinib" is usually found in some domestic drug instructions, hospital medication systems or medical insurance catalogs, while "Brigatinib" is more commonly seen in early media reports, some academic papers or patient communities. In the registration information of the State Food and Drug Administration, the drug is officially marketed as "Brigatinib Tablets". Therefore, in the Chinese market, "Brigatinib" is a more authoritative and standardized name. But in essence, no matter which name you choose, they all refer to the same targeted drug.

Therefore, when inquiring about drugs or purchasing them, it is best for patients to directly look up the English generic name"Brigatinib", or check the chemical name and registration information of the drug to ensure that they are using regular and legal treatment drugs. At the same time, it is also recommended that doctors clearly state that the different Chinese names are actually the same drug when prescribing or conducting patient education to reduce misunderstandings.

Reference materials:https://www.alunbrig.com/